BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma.

BRD9 degradation enhances GBAF chromatin remodeling activity in synovial sarcoma, undermining therapeutic efforts with minimal impact on tumor proliferation.

• Why it matters: Understanding why BRD9 degraders failed in clinical trials is crucial, as it reveals the resilience of GBAF complexes and the limitations of targeting BRD9 alone in synovial sarcoma.
• What they did: The study used cellular, xenograft, and biochemical approaches to analyze the effects of BRD9 loss, finding that BRD9 depletion increased GBAF activity and chromatin accessibility despite reduced target locus enrichment.
• The result: Enhanced GBAF activity due to BRD9 loss promotes gene transcription and chromatin remodeling, creating a subtle epigenetic shift that limits the therapeutic potential of BRD9 degraders in synovial sarcoma.